Skip to main content
Policy & Funding· Daily Pulse

Washington Is Finally Funding Ibogaine Research. It's Borrowing the Safety Record From a Clinic That Sells the Trip.

HHS will put up to $4.9 million into preparing ibogaine studies, using data from a Mexico clinic that has dosed 3,000 people. Addiction comes later, maybe.

ByThe Rize NewsroomNovember 19, 20262 min readPsychedelics & Empathogens

For years, the people most desperate for ibogaine have been people trying to get off opioids, flying to clinics in Mexico because nothing at home had held. Last Thursday the federal government finally put money behind the drug. It put that money behind veterans with PTSD first, and it is getting its early evidence from one of those clinics.

Public money for ibogaine is overdue. Letting a company that sells ibogaine treatments supply the starting safety record is not how you earn public trust.

On Nov. 12, Health Secretary Robert F. Kennedy Jr. announced that ARPA-H, the government’s high-risk research agency, will spend up to $4.9 million over five years to lay the groundwork for ibogaine trials: manufacturing, dosing and study design, not treating patients. HHS was explicit that the money does not fund “treatment of patients or human-subject research.” Mark Cuban’s Cost Plus Drugs will work on U.S. manufacturing. And Beond Ibogaine, a Texas company running a licensed clinic in Mexico that has treated more than 3,000 patients with 6,000 doses, will hand its clinical data to the government’s research teams. Kennedy said that “is going to allow us to dramatically accelerate the clinical trial process.” Ibogaine for substance use disorders, he said, will be a later award.

The reason to slow down is the heart. Ibogaine can disrupt the electrical rhythm that keeps the heart beating, and HHS itself calls those rhythm problems potentially life-threatening. The best U.S. data so far, a Stanford study in Nature Medicine, gave ibogaine with magnesium, added to protect the heart, to 30 special operations veterans at a Mexico clinic and reported large drops in PTSD, depression and anxiety. It was an observational study with no comparison group, in carefully screened men, not a trial. Clinic records are useful. They are also records kept by a business that profits when the treatment looks safe, and they rarely capture who had a bad night and never came back.

If you are someone weighing a trip south for opioid withdrawal, the honest status hasn’t changed this week. Ibogaine is still a Schedule I drug at home, and no federal study in this package doses anyone. The cardiac risk is real, and it is worse when other drugs that strain the heart are still in your system. Our earlier report on a noribogaine compound heading toward FDA-supervised trials and our psychedelics coverage track the safer road.

For clinicians, the useful move is to ask. Add ibogaine to the substances you ask about at intake, without judgment, especially with veterans and people with long opioid histories, and get an ECG on anyone who’s been or is planning to go.

The government finally said ibogaine is worth studying. Now it has to prove it can study it without taking the seller’s word for it.

Filed Under

policysciencesocial-culturalIbogainePsychedelics (general)VeteransFundingFederal

Keep up with the reporting.

One email each morning with the stories that put days like this in context.

A daily, no-spam briefing. Unsubscribe anytime.

Continue reading

More from this section